Linked Life Data

8932505

Source:http://linkedlifedata.com/resource/pubmed/id/8932505

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-3-28
pubmed:abstractText
Staphylococcus aureus, especially multidrug resistant strains, continues to be a leading cause of serious nosocomial infections. In spite of the debate among investigators in the field, the discovery of serologically distinct capsular polysaccharides on the surface of clinical isolates has renewed the prospects for development of vaccines and passive protective immunity against S. aureus infections. Capsular polysaccharide conjugate vaccines have now been produced and proven to be safe and immunogenic in both healthy and in a significant percentage of immunocompromised patients. Antibodies generated in humans against these vaccines have been shown to mediate type-specific opsonophagocytosis, and to protect animals against lethal challenge with the appropriate S. aureus isolate.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0785-3890
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
43-6
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Staphylococcal vaccines: a realistic dream.
pubmed:affiliation
Univax Biologics Inc., Rockville, MD 20852, USA.
pubmed:publicationType
Journal Article, Review